Before testing an AI summary for one internal administrative task, we suggest a broker-dealer's appointed business and technology reviewers agree on six things: the task, the firm-approved tool, the text allowed in the trial, how each summary is checked against its source, what counts as failure, and who decides afterwards. Start with public or synthetic text, and keep a person responsible for every decision.
Who this is for
This guide is for a home-office operations, compliance or technology group that the firm has asked to evaluate one narrow administrative use. An example is an AI-generated summary of a long public document that helps staff find the relevant section. The aim is to learn whether such a summary is accurate enough to help, without moving any decision away from the people accountable for it.
It is not written for independent RIAs. If your firm is dually registered, its qualified people decide how any of this applies. The guide does not suggest that branch or individual staff buy or connect tools on their own. The firm's existing approval path, approved platforms and supervision processes come first.
What the regulator has described
FINRA's 2026 oversight report section on generative AI is addressed to member firms. It says FINRA's rules, which are intended to be technologically neutral, continue to apply when firms use GenAI. It lists internal information retrieval and summarization or information extraction among the uses it has observed (FINRA 2026 oversight report: GenAI; Product check: 1 November 2026).
The report groups points firms may want to consider under general risk approaches, supervision and governance, testing, and monitoring. Among them are formal review and approval processes involving business and technology experts, and testing for privacy, integrity, reliability and accuracy. They also include monitoring that can involve keeping prompt and output logs, tracking which model version was used, and human review of outputs.
That is useful context, not a complete control list. This guide is not a compliance checklist or legal opinion. How any of it applies to your firm is for the firm's qualified people to decide.
Narrow the task first
A trial is easier to read when the task is small and the text is safe. Candidates include summaries of documents the firm already treats as public, or documents the team writes specifically for testing. At a minimum, we suggest keeping the following out of the trial. Your firm may exclude more.
- customer communications
- account data and personal information about customers, prospects or staff
- firm-confidential material
- credentials or system access details
- anything touching supervision conclusions or investment recommendations
- any tool that takes actions on its own rather than producing text for a person to review
Questions for the approval team
| Question | Why it matters |
|---|---|
| Who in the firm owns this evaluation on the business side, and who on the technology side? | Keeps the decision with appointed people. |
| Which firm-approved tool will be used, and through which existing access? | Prevents side-channel tools and ad hoc accounts. |
| Has the firm's own review covered how that tool handles the trial text, and who confirmed it? | Privacy and data handling stay firm decisions. This guide sets no rules for them. |
| What is the exact task: one document type and one summary format? | A narrow scope makes results readable. |
| What text is allowed in the trial? | At this stage, public or synthetic text only. |
| How will each summary be checked against its source, and by whom? | A person judges accuracy against the original. |
| What counts as a failure? | Agree on it before anyone sees results. |
| Where will test inputs, the instructions given to the tool, the tool and model version, outputs and reviewer notes be kept? | Lets a rerun be compared and the evaluation be reviewed later, under the firm's own record-keeping decisions. |
| Who decides whether to stop, revise or extend, and what would extending require? | A trial result is not an approval. |
These questions are our editorial suggestion for structuring the conversation. They are not a regulator's list.
A source-to-summary check
For each summary in the trial, a reviewer compares it with the original and confirms:
- Every statement traces to a specific passage in the source.
- Dates, numbers, names and defined terms match the source.
- Conditions and qualifiers survive: “may” has not become “must”, and no exceptions are dropped.
- Nothing important for the stated purpose is missing.
- No recommendation, conclusion or instruction appears that the source does not contain.
- The reviewer's name, the date and a pass or fail note are recorded.
Smaller firm or larger home office
Firm size changes the practical shape of a trial, not who decides. Where one person holds several roles, writing down who answered each question keeps the record clear. Whether anyone else must review the results is set by the firm's own approval path.
Where business owners, technology reviewers and compliance contacts sit in different groups, one named evaluation owner and one place for the record can help keep the trial coordinated.
Synthetic example, not a customer result
A fictional firm's appointed evaluation owner chooses one task: one-paragraph summaries of a public regulatory notice and three synthetic internal memos the team wrote for the test. Using the firm's approved platform, the team generates twelve summaries and records the instructions and model version used. The assigned reviewers check each one against its source using the source-to-summary check above. Their notes show that two summaries turned a conditional statement into a firm requirement and one dropped an effective date. The owner records the findings and decides to revise the instructions and rerun the test with the same record, rather than extend use. No real firm, document set or outcome is described here.
A next step
Before anything else, identify the person your firm has authorized to own this kind of evaluation. Share these questions with them and read the FINRA section linked above together. Any tool choice, test design or decision to proceed stays with that owner and the firm's approval process.
Sources
Product documentation checked 1 November 2026. Features depend on the current plan, permissions and setup.